Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spire Healthcare GroupCHIX:SPIL -0.46%75 EV-to-EBITDA is 8.92 as of Jul. 20, 2026, which is 9% below its 10-year median of 9.80. GuruFocus rates CHIX:SPIL with a GF Score™ of 75/100 and a GF Value™ of £2.71 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Spire Healthcare Group ranks better than 60.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Spire Healthcare Group's enterprise value is £2,155 Mil.
Spire Healthcare Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £242 Mil. Therefore, Spire Healthcare Group's EV-to-EBITDA for today is 8.92.
The historical rank and industry rank for Spire Healthcare Group's EV-to-EBITDA or its related term are showing as below:
CHIX:SPIl'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -40 Med: 9.8 Max: 21.12
Current: 8.92
During the past 13 years, the highest EV-to-EBITDA of Spire Healthcare Group was 21.12. The lowest was -40.00. And the median was 9.80.
CHIX:SPIl's EV-to-EBITDA is ranked better than 60.67% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.1
vs CHIX:SPIl: 8.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Spire Healthcare Group (CHIX:SPIl) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Spire Healthcare Group's PE Ratio (TTM) for today is calculated as:
Spire Healthcare Group's share price for today is £2.185.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spire Healthcare Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SPIL vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Spire Healthcare Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spire Healthcare Group EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Spire Healthcare Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Spire Healthcare Group's EV-to-EBITDA falls into.
Spire Healthcare Group's current Enterprise Value is £2,155 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spire Healthcare Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £242 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spire Healthcare Group (CHIX:SPIL) has a EV-to-EBITDA of 8.92 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Spire Healthcare Group. This is near median its historical median of 9.80. According to the industry distribution chart, Spire Healthcare Group ranks #199 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 39.3%.
Is Spire Healthcare Group's EV-to-EBITDA too high?
Spire Healthcare Group's current EV-to-EBITDA of 8.92 is near median its 10-year median of 9.80. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.10. Spire Healthcare Group's value of 8.92 is 19.6% below this industry median. Based on the distribution chart, Spire Healthcare Group ranks #199 out of 506 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Spire Healthcare Group has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Spire Healthcare Group's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Spire Healthcare Group ranks #199 out of 506 companies for EV-to-EBITDA. This puts Spire Healthcare Group in the upper half of its industry. The industry median EV-to-EBITDA is 11.10. Spire Healthcare Group's value of 8.92 is 19.6% below this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 11.10, Spire Healthcare Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.10, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spire Healthcare Group's current EV-to-EBITDA of 8.92 is 19.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Spire Healthcare Group. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spire Healthcare Group's current EV-to-EBITDA is 8.92, which is near median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spire Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, Spire Healthcare Group (CHIX:SPIL) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.71, compared to a current price of £2.19 — trading 19.4% below its estimated fair value. The current EV-to-EBITDA is 8.92, which is near median its 10-year median of 9.80 and 19.6% below the Healthcare Providers & Services industry median of 11.10. Spire Healthcare Group's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Spire Healthcare Group (CHIX:SPIL), the current EV-to-EBITDA is 8.92 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spire Healthcare Group (CHIX:SPIL) Overvalued in 2026?
Based on GuruFocus' analysis, Spire Healthcare Group stock appears to be undervalued.
The current stock price of £2.19 is trading 19.4% below its estimated GF Value™ of £2.71.
GuruFocus considers Spire Healthcare Group to be Modestly Undervalued.
Key valuation signals for CHIX:SPIL:
EV-to-EBITDA: 8.92 (near median its 10-year median of 9.80)
GF Value™: £2.71 vs. price of £2.19 (19.4% below fair value)
Industry Position: 19.6% below the Healthcare Providers & Services median (#199 of 506)
No single metric tells the full story. See the CHIX:SPIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spire Healthcare Group PLC is an independent hospital group in the United Kingdom. It is a private provider, by volume, of knee and hip operations in the United Kingdom. The company has two operating segments: the hospitals business and the Primary care. The company generates the majority of its revenue from Hospital Business, which consists of hospitals, clinics, medical centres and consulting rooms. The company provide diagnostics, inpatient, day case and outpatient care in areas including orthopaedics, gynaecology, cardiology, neurology, oncology and general surgery. The primary care segment encompasses services focused on the primary care needs of outpatients, including GP services, occupational health services or mental and physical health services.
75GF Score
Get the complete analysis for CHIX:SPIL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SPIL has been successfully added to your 
